Phaseline

Companies › Viatris Innovation

Viatris Innovation: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 3, 1 Phase 1; Immunology, Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cenerimod
Sphingosine 1-phosphate receptor Edg-1 modulator
S1PR1Phase 3Lupus Erythematosus, Systemic; Nephritis, LupusDec 2026
Selatogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 1Chronic Coronary Syndrome–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07615868SelatogrelPhase 1Chronic Coronary SyndromeCardiovascularSep 2026
NCT05672576CenerimodPhase 3Lupus Erythematosus, SystemicImmunologyDec 2026
NCT05648500CenerimodPhase 3Lupus Erythematosus, SystemicImmunologyMar 2027
NCT07201129CenerimodPhase 3Nephritis, LupusImmunologyAug 2029

Targets

S1PR1 (1) P2RY12 (1)

Companies with the same targets

Novartis Boehringer Ingelheim Vanda Pharmaceuticals Bristol-Myers Squibb Pfizer Priothera SAS Aptabio Therapeutics iVascular S.L.U. Jiangsu vcare pharmaceutical technology

Companies built like this

Jiangsu vcare pharmaceutical technology HK inno.N Prime Gene Therapeutics Hangzhou Highlightll Pharmaceutical HELP Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.